keyword
MENU ▼
Read by QxMD icon Read
search

"no evidence of disease activity" AND "multiple sclerosis"

keyword
https://www.readbyqxmd.com/read/30539030/safety-and-efficacy-of-rituximab-in-multiple-sclerosis-a-retrospective-observational-study
#1
Bassem I Yamout, Nabil K El-Ayoubi, Johny Nicolas, Yehya El Kouzi, Samia J Khoury, Maya M Zeineddine
Objective: To evaluate the efficacy and safety of rituximab in multiple sclerosis in a clinical practice setting. Methods: Clinical data for all adult patients with multiple sclerosis (MS) treated with off-label rituximab at a single MS center in Lebanon between March 2008 and April 2017 were retrospectively collected from medical charts. The main efficacy outcomes assessed were annualized relapse rate (ARR) and proportion of patients free from relapses, disability progression, or magnetic resonance imaging (MRI) activity...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/30513578/multiple-sclerosis-a-global-concern-with-multiple-challenges-in-an-era-of-advanced-therapeutic-complex-molecules-and-biological-medicines
#2
Victor M Rivera
Multiple sclerosis (MS) has become a common neurological disorder involving populations previously considered to be infrequently affected. Genetic dissemination from high- to low-risk groups is a determining influence interacting with environmental and epigenetic factors, mostly unidentified. Disease modifying therapies (DMT) are effective in treating relapsing MS in variable degrees; one agent is approved for primary progressive disease, and several are in development. In the era of high-efficacy medications, complex molecules, and monoclonal antibodies (MAB), including anti-VLA4 (natalizumab), anti-CD52 (alemtuzumab), and anti-CD20 (ocrelizumab), obtaining NEDA (no evidence of disease activity) becomes an elusive accomplishment in areas of the world where access to MS therapies and care are generally limited...
November 30, 2018: Biomedicines
https://www.readbyqxmd.com/read/30513503/acquired-haemophilia-a-as-a-secondary-autoimmune-disease-after-alemtuzumab-treatment-in-multiple-sclerosis-a-case-report
#3
M Pisa, P Della Valle, A Coluccia, V Martinelli, G Comi, A D'Angelo, L Moiola
Alemtuzumab is a highly effective monoclonal antibody for the treatment of multiple sclerosis (MS). During the immune reconstitution following the use of this treatment severe secondary autoimmune diseases (SADs) can develop. We present the case of a patient affected by active MS who failed to achieve disease control with several disease-modifying drugs and was thereafter successfully treated with alemtuzumab, obtaining no evidence of disease activity and a high quality of life. Twenty months after the first infusion of alemtuzumab the patient developed acquired haemophilia A (AHA), a treatable but potentially lifethreatening condition that should be considered a possible SADs associated to this drug...
November 29, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/30443887/immune-reconstitution-therapy-irt-in-multiple-sclerosis-the-rationale
#4
REVIEW
Dimitrios Karussis, Panayiota Petrou
Immunotherapy of multiple sclerosis (MS) and other neuroimmune diseases is rapidly evolving. For the past 25 years, there has been an accelerating inclusion of new immunomodulating drugs. Based on their molecular construction and their basic mechanism of action, immunotherapeutic agents belong to the following categories: (1) cytotoxic drugs, (2) synthetic immunomodulators, (3) monoclonal antibodies, (4) vaccines (T cell vaccines, antigen vaccines), (5) oral tolerizing agents, (6) modalities that act as indirect immunosuppressants (plasmapheresis, intravenous immunoglobulins [IVIG]), and (7) cellular therapies...
November 16, 2018: Immunologic Research
https://www.readbyqxmd.com/read/30401571/brain-volume-loss-and-no-evidence-of-disease-activity-over-3-years-in-multiple-sclerosis-patients-under-interferon-beta-1a-subcutaneous-treatment
#5
J I Rojas, F Sanchez, F Caro, J Miguez, L Patrucco, J Funes, E Cristiano
The objective of our study was to evaluate the relationship of percentage of annualized brain volume loss (aBVL) and no evidence of disease activity (NEDA) in multiple sclerosis (MS) patients under interferon beta 1-a subcutaneous treatment (IFN-beta) during 3 years of follow up. Relapsing remitting MS (RRMS) patients, with less than three years from disease onset, expanded disability status scale (EDSS) ≤3 and in which IFN beta 1-a 44 mcg was indicated, were included. Demographic, clinical and structural parameters from the magnetic resonance (MR) during the 3 years of follow up were analyzed and compared between patients with and without NEDA (defined as the absence of: (a) three-month confirmed disability progression defined as an increase in EDSS score of 1...
November 3, 2018: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/30384198/no-evidence-of-disease-activity-status-over-3-years-in-a-real-world-cohort-of-relapsing-remitting-ms-patients-in-germany
#6
Konstantin Huhn, Daniela Senger, Kathrin S Utz, Manuel Schmidt, Kilian Fröhlich, Anne Waschbisch, Frank Seifert, Arnd Dörfler, De-Hyung Lee, Ralf A Linker
BACKGROUND: Over the last decade, therapy of relapsing remitting multiple sclerosis (RRMS) has evolved with the approval of several new treatment concepts. Thus, treatment goals have become more ambitious aiming at "no evidence of disease activity" (NEDA). As NEDA-3, this concept comprises freedom of clinical disease progression and relapses as well as inflammatory MRI activity. So far, data on NEDA status mainly stem from post-hoc analyses of drug approval studies. Yet, less is known about the significance of NEDA in "real-world" clinical settings...
October 23, 2018: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/30375760/real-world-effectiveness-of-disease-modifying-therapies-in-korean-patients-with-relapsing-multiple-sclerosis
#7
Su Hyun Kim, Min Su Park, Woojun Kim, So Young Huh, Hyun June Shin, Jae Won Hyun, Ho Jin Kim
BACKGROUND AND PURPOSE: This study assessed the long-term outcomes of disease-modifying therapies (DMTs) in Korean multiple sclerosis (MS) patients treated in real-world clinical settings in Korea. METHODS: We retrospectively evaluated the medical records of 160 patients with an initial diagnosis of clinically isolated syndrome or relapsing-remitting MS who were treated for at least 2 years. A status of 3 for no evidence of disease activity (NEDA3) was defined as no relapse, disability progression, or active lesions in annual magnetic resonance imaging (MRI) evaluations...
October 26, 2018: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/30259178/no-evidence-of-disease-activity-neda-3-and-disability-improvement-after-alemtuzumab-treatment-for-multiple-sclerosis-a-36-month-real-world-study
#8
Luca Prosperini, Pietro Annovazzi, Laura Boffa, Maria Chiara Buscarinu, Antonio Gallo, Manuela Matta, Lucia Moiola, Luigina Musu, Paola Perini, Carlo Avolio, Valeria Barcella, Assunta Bianco, Deborah Farina, Elisabetta Ferraro, Simona Pontecorvo, Franco Granella, Luigi M E Grimaldi, Alice Laroni, Giacomo Lus, Francesco Patti, Eugenio Pucci, Matteo Pasca, Paola Sarchielli
In this retrospective, multicenter, real-world study we collected clinical and magnetic resonance imaging (MRI) data of all patients (n = 40) with relapsing-remitting multiple sclerosis (RRMS) treated with alemtuzumab according to a "free-of-charge" protocol available before the drug marketing approval in Italy. Almost all (39/40) started alemtuzumab after discontinuing multiple disease-modifying treatments (DMTs) because of either lack of response or safety concerns. We considered the proportion of alemtuzumab-treated patients who had no evidence of disease activity (NEDA-3) and disability improvement over a 36-month follow-up period...
December 2018: Journal of Neurology
https://www.readbyqxmd.com/read/30234431/silent-lesions-on-mri-imaging-shifting-goal-posts-for-treatment-decisions-in-multiple-sclerosis
#9
Myintzu Min, Tim Spelman, Alessandra Lugaresi, Cavit Boz, Daniele LA Spitaleri, Eugenio Pucci, Francois Grand'Maison, Franco Granella, Guillermo Izquierdo, Helmut Butzkueven, Jose Luis Sanchez-Menoyo, Michael Barnett, Marc Girard, Maria Trojano, Pierre Grammond, Pierre Duquette, Patrizia Sola, Raed Alroughani, Raymond Hupperts, Steve Vucic, Tomas Kalincik, Vincent Van Pesch, Jeannette Lechner-Scott
BACKGROUND: The current best practice suggests yearly magnetic resonance imaging (MRI) to monitor treatment response in multiple sclerosis (MS) patients. OBJECTIVE: To evaluate the current practice of clinicians changing MS treatment based on subclinical new MRI lesions alone. METHODS: Using MSBase, an international MS patient registry with MRI data, we analysed the probability of treatment change among patients with clinically silent new MRI lesions...
October 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/30217172/effect-of-interferon-beta-1a-subcutaneously-three-times-weekly-on-clinical-and-radiological-measures-and-no-evidence-of-disease-activity-status-in-patients-with-relapsing-remitting-multiple-sclerosis-at-year-1
#10
RANDOMIZED CONTROLLED TRIAL
Anthony Traboulsee, David K B Li, Mark Cascione, Juanzhi Fang, Fernando Dangond, Aaron Miller
BACKGROUND: In the PRISMS study, interferon beta-1a subcutaneously (IFN β-1a SC) reduced clinical and radiological disease burden at 2 years in patients with relapsing-remitting multiple sclerosis. The study aimed to characterize efficacy of IFN β-1a SC 44 μg and 22 μg three times weekly (tiw) at Year 1. METHODS: Exploratory endpoints included annualized relapse rate (ARR), 3-month confirmed disability progression (1-point Expanded Disability Status Scale increase if baseline was < 6...
September 14, 2018: BMC Neurology
https://www.readbyqxmd.com/read/30181780/peginterferon-%C3%AE-1a-every-2-weeks-increased-achievement-of-no-evidence-of-disease-activity-over-4-years-in-the-advance-and-attain-studies-in-patients-with-relapsing-remitting-multiple-sclerosis
#11
Douglas L Arnold, Shulian Shang, Qunming Dong, Matthias Meergans, Maria L Naylor
Background: No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing-remitting multiple sclerosis (RRMS). Objective: To assess the NEDA status of patients treated with peginterferon β-1a in the ADVANCE and ATTAIN studies and explore its predictive value on longer-term clinical outcomes. Methods: ATTAIN was a 2-year extension of the pivotal 2-year ADVANCE study of peginterferon β-1a for RRMS...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/30116299/long-term-evaluation-of-neda-3-status-in-relapsing-remitting-multiple-sclerosis-patients-after-switching-from-natalizumab-to-fingolimod
#12
Lara Diem, Krassen Nedeltchev, Timo Kahles, Lutz Achtnichts, Oliver Findling
Background: Natalizumab significantly reduces the disease activity in patients with relapsing-remitting multiple sclerosis but due to the risk of progressive multifocal leukoencephalopathy it is often discontinued. Fingolimod is seen as an alternative, but there are no long-term analyses of the efficacy of fingolimod in this setting using the no evidence of disease activity (NEDA)-3 criteria. We provide an assessment of patients who discontinued natalizumab and switched to fingolimod or other treatments by evaluating the proportion of patients who fulfil NEDA-3 criteria after prolonged follow-up periods...
2018: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/30102815/no-evidence-of-disease-activity-in-people-with-multiple-sclerosis
#13
EDITORIAL
M Marta
No abstract text is available yet for this article.
August 13, 2018: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
https://www.readbyqxmd.com/read/30090102/immunophenotype-and-transcriptome-profile-of-patients-with-multiple-sclerosis-treated-with-fingolimod-setting-up-a-model-for-prediction-of-response-in-a-2-year-translational-study
#14
Irene Moreno-Torres, Coral González-García, Marco Marconi, Aranzazu García-Grande, Luis Rodríguez-Esparragoza, Víctor Elvira, Elvira Ramil, Lucía Campos-Ruíz, Ruth García-Hernández, Fátima Al-Shahrour, Coral Fustero-Torre, Alicia Sánchez-Sanz, Antonio García-Merino, Antonio José Sánchez López
Background: Fingolimod is a functional sphingosine-1-phosphate antagonist approved for the treatment of multiple sclerosis (MS). Fingolimod affects lymphocyte subpopulations and regulates gene expression in the lymphocyte transcriptome. Translational studies are necessary to identify cellular and molecular biomarkers that might be used to predict the clinical response to the drug. In MS patients, we aimed to clarify the differential effects of fingolimod on T, B, and natural killer (NK) cell subsets and to identify differentially expressed genes in responders and non-responders (NRs) to treatment...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/30033621/assessing-the-role-of-innovative-therapeutic-paradigm-on-multiple-sclerosis-treatment-response
#15
Marzia A L Romeo, Vittorio Martinelli, Gloria Dalla Costa, Bruno Colombo, Donatella De Feo, Federica Esposito, Laura Ferrè, Clara Guaschino, Simone Guerrieri, Giuseppe Liberatore, Filippo Martinelli Boneschi, Arianna Merlini, Mariajosè Messina, Roberta Messina, Arturo Nuara, Paolo Preziosa, Marta Radaelli, Maria A Rocca, Mariaemma Rodegher, Francesca Sangalli, Davide Strambo, Lucia Moiola, Giancarlo Comi
OBJECTIVE: Within the last decade, many changes have been made to the management of patients with multiple sclerosis (MS). The aim of our study was to investigate the global impact of all these changes on the disease's course. MATERIALS AND METHODS: This single-centre study was carried out on patients with multiple sclerosis (pwMS) who started treatment with first-line disease-modifying therapies. We have compared three large cohorts of patients with MS diagnosis, for three consecutive periods within July 2001, August 2001-December 2005, and January 2006-September 2011...
July 22, 2018: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/30021640/neurofilament-levels-disease-activity-and-brain-volume-during-follow-up-in-multiple-sclerosis
#16
Irene Håkansson, Anders Tisell, Petra Cassel, Kaj Blennow, Henrik Zetterberg, Peter Lundberg, Charlotte Dahle, Magnus Vrethem, Jan Ernerudh
BACKGROUND: There is a need for clinically useful biomarkers of disease activity in clinically isolated syndrome (CIS) and relapsing remitting MS (RRMS). The aim of this study was to assess the correlation between neurofilament light chain (NFL) in cerebrospinal fluid (CSF) and serum and the relationship between NFL and other biomarkers, subsequent disease activity, and brain volume loss in CIS and RRMS. METHODS: A panel of neurodegenerative and neuroinflammatory markers were analyzed in repeated CSF samples from 41 patients with CIS or RRMS in a prospective longitudinal cohort study and from 22 healthy controls...
July 18, 2018: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29974307/brain-volume-loss-is-present-in-japanese-multiple-sclerosis-patients-with-no-evidence-of-disease-activity
#17
Hiroaki Yokote, Tomoyuki Kamata, Shuta Toru, Nobuo Sanjo, Takanori Yokota
No evidence of disease activity-3 (NEDA-3), defined as absence of clinical relapse, disability progression, and brain magnetic resonance imaging (MRI) activity, has emerged as the therapeutic target of disease-modifying therapy for multiple sclerosis (MS). However, recent studies have revealed that NEDA-3 might not be sufficient to prevent cognitive deterioration and predict long-term disability. In addition to NEDA-3, brain atrophy has recently been recognized as a pivotal biomarker that is closely associated to disability in patients with MS...
October 2018: Neurological Sciences
https://www.readbyqxmd.com/read/29938336/the-effect-of-fingolimod-on-focal-and-diffuse-grey-matter-damage-in-active-ms-patients
#18
Albulena Bajrami, Marco Pitteri, Marco Castellaro, Francesca Pizzini, Chiara Romualdi, Stefania Montemezzi, Salvatore Monaco, Massimiliano Calabrese
INTRODUCTION: The mechanism of action of fingolimod within the central nervous system and its efficacy in reducing/preventing both focal and diffuse grey matter (GM) damage in active multiple sclerosis (MS) are not completely understood. METHODS: In this longitudinal, 2-year prospective, phase IV, single-blind study, 40 MS patients treated with fingolimod and 39 untreated age, gender, and disability-matched MS patients were enrolled. Each patient underwent a neurological examination every 6 months and a 3T MRI at the beginning of the treatment and after 24 months...
June 25, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29928650/the-nrf2-pathway-as-potential-biomarker-for-dimethyl-fumarate-treatment-in-multiple-sclerosis
#19
Anna Hammer, Anne Waschbisch, Kristina Kuhbandner, Antonios Bayas, De-Hyung Lee, Alexander Duscha, Aiden Haghikia, Ralf Gold, Ralf A Linker
Objective: Immunological studies have demonstrated a plethora of beneficial effects of dimethyl fumarate (DMF) on various cell types. However, the cellular and molecular targets are incompletely understood and response markers are scarce. Here, we focus on the relation between nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway induction under DMF therapy and the composition of the blood immune cell compartment and clinical efficacy in relapsing-remitting multiple sclerosis (MS) patients...
June 2018: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/29870645/-alemtuzumab-therapy-2017
#20
REVIEW
Tamás Biernacki, Krisztina Bencsik, Dániel Sandi, László Vécsei
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system comprising of inflammation, demyelinisation and neurodegeneration. The natural history of MS is heterogenous. Owing to the vast range and severity of the symptoms MS can cause the effect of the disease on one's cognitive and physical status is unpredictable. According to the new, phenotype based classification two subgroups can be distinguished; relapsing-remitting (RR) and progressive MS. Relapsing-remitting MS can be further divided into active and inactive disease...
November 30, 2017: Ideggyógyászati Szemle
keyword
keyword
158176
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"